Literature DB >> 30121132

Histotype classification of ovarian carcinoma: A comparison of approaches.

Lauren C Peres1, Kara L Cushing-Haugen2, Michael Anglesio3, Kristine Wicklund2, Rex Bentley4, Andrew Berchuck5, Linda E Kelemen6, Tayyebeh M Nazeran7, C Blake Gilks7, Holly R Harris2, David G Huntsman7, Joellen M Schildkraut8, Mary Anne Rossing2, Martin Köbel9, Jennifer A Doherty10.   

Abstract

OBJECTIVE: Major changes in the classification of ovarian carcinoma histotypes occurred over the last two decades, resulting in the current 2014 World Health Organization (WHO) diagnostic criteria that recognize five principal histotypes: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous carcinoma. We assessed the impact of these guidelines and use of immunohistochemical (IHC) markers on classification of ovarian carcinomas in existing population-based studies.
METHODS: We evaluated histotype classification for 2361 ovarian carcinomas diagnosed between 1999 and 2009 from two case-control studies using three approaches: 1. pre-2014 WHO ("historic") histotype; 2. Standardized review of pathology slides using the 2014 WHO criteria alone; and 3. An integrated IHC assessment along with the 2014 WHO criteria. We used Kappa statistics to assess agreement between approaches, and Kaplan-Meier survival curves and Cox proportional hazards models to evaluate mortality.
RESULTS: Compared to the standardized pathologic review histotype, agreement across approaches was high (kappa = 0.892 for historic, and 0.849 for IHC integrated histotype), but the IHC integrated histotype identified more low-grade serous carcinomas and a subset of endometrioid carcinomas that were assigned as high-grade serous (n = 25). No substantial differences in histotype-specific mortality were observed across approaches.
CONCLUSIONS: Our findings suggest that histotype assignment is fairly consistent regardless of classification approach, but that progressive improvements in classification accuracy for some less common histotypes are achieved with pathologic review using the 2014 WHO criteria and with IHC integration. We additionally recommend a classification scheme to fit historic data into the 2014 WHO categories to answer histotype-specific research questions.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histotype; Ovarian carcinoma; Stage; Survival

Mesh:

Substances:

Year:  2018        PMID: 30121132      PMCID: PMC6292681          DOI: 10.1016/j.ygyno.2018.08.016

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  34 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications.

Authors:  B Lund; H K Thomsen; J Olsen
Journal:  APMIS       Date:  1991-04       Impact factor: 3.205

3.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

Review 4.  Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.

Authors:  Helen J Mackay; Mark F Brady; Amit M Oza; Alexander Reuss; Eric Pujade-Lauraine; Ann M Swart; Nadeem Siddiqui; Nicoletta Colombo; Michael A Bookman; Jacobus Pfisterer; Andreas du Bois
Journal:  Int J Gynecol Cancer       Date:  2010-08       Impact factor: 3.437

5.  Calculator for ovarian carcinoma subtype prediction.

Authors:  Steve E Kalloger; Martin Köbel; Samuel Leung; Erika Mehl; Dongxia Gao; Krista M Marcon; Christine Chow; Blaise A Clarke; David G Huntsman; C Blake Gilks
Journal:  Mod Pathol       Date:  2010-12-03       Impact factor: 7.842

6.  Interobserver variability in the interpretation of epithelial ovarian cancer.

Authors:  E Hernandez; B S Bhagavan; T H Parmley; N B Rosenshein
Journal:  Gynecol Oncol       Date:  1984-01       Impact factor: 5.482

7.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

8.  Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

Authors:  John K Chan; Deanna Teoh; Jessica M Hu; Jacob Y Shin; Kathryn Osann; Daniel S Kapp
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482

9.  Menopausal hormone therapy and risk of epithelial ovarian cancer.

Authors:  Mary Anne Rossing; Kara L Cushing-Haugen; Kristine G Wicklund; Jennifer A Doherty; Noel S Weiss
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

10.  Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.

Authors:  Martin Köbel; Anna M Piskorz; Sandra Lee; Shuhong Lui; Cecile LePage; Francesco Marass; Nitzan Rosenfeld; Anne-Marie Mes Masson; James D Brenton
Journal:  J Pathol Clin Res       Date:  2016-07-13
View more
  14 in total

1.  Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study.

Authors:  Chun-Pin Chang; Yuji Chen; Brenna Blackburn; Sarah Abdelaziz; Kerry Rowe; John Snyder; Mark Dodson; Vikrant Deshmukh; Michael Newman; Joseph B Stanford; Christina A Porucznik; Jennifer Ose; Alison Fraser; Ken Smith; Jennifer Doherty; David Gaffney; Mia Hashibe
Journal:  Gynecol Oncol       Date:  2020-02-29       Impact factor: 5.482

2.  Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).

Authors:  Aline Talhouk; Joshy George; Chen Wang; Ellen L Goode; Susan J Ramus; Jennifer A Doherty; David D Bowtell; Michael S Anglesio; Timothy Budden; Tuan Zea Tan; Derek S Chiu; Stefan Kommoss; Huei San Leong; Stephanie Chen; Maria P Intermaggio; Blake Gilks; Tayyebeh M Nazeran; Mila Volchek; Wafaa Elatre; Rex C Bentley; Janine Senz; Amy Lum; Veronica Chow; Hanwei Sudderuddin; Robertson Mackenzie; Samuel C Y Leong; Geyi Liu; Dustin Johnson; Billy Chen; Aocs Group; Jennifer Alsop; Susana N Banerjee; Sabine Behrens; Clara Bodelon; Alison H Brand; Louise Brinton; Michael E Carney; Yoke-Eng Chiew; Kara L Cushing-Haugen; Cezary Cybulski; Darren Ennis; Sian Fereday; Renée T Fortner; Jesús García-Donas; Aleksandra Gentry-Maharaj; Rosalind Glasspool; Teodora Goranova; Casey S Greene; Paul Haluska; Holly R Harris; Joy Hendley; Brenda Y Hernandez; Esther Herpel; Mercedes Jimenez-Linan; Chloe Karpinskyj; Scott H Kaufmann; Gary L Keeney; Catherine J Kennedy; Martin Köbel; Jennifer M Koziak; Melissa C Larson; Jenny Lester; Liz-Anne Lewsley; Jolanta Lissowska; Jan Lubiński; Hugh Luk; Geoff Macintyre; Sven Mahner; Iain A McNeish; Janusz Menkiszak; Nikilyn Nevins; Ana Osorio; Oleg Oszurek; José Palacios; Samantha Hinsley; Celeste L Pearce; Malcolm C Pike; Anna M Piskorz; Isabelle Ray-Coquard; Valerie Rhenius; Cristina Rodriguez-Antona; Raghwa Sharma; Mark E Sherman; Dilrini De Silva; Naveena Singh; Peter Sinn; Dennis Slamon; Honglin Song; Helen Steed; Euan A Stronach; Pamela J Thompson; Aleksandra Tołoczko; Britton Trabert; Nadia Traficante; Chiu-Chen Tseng; Martin Widschwendter; Lynne R Wilkens; Stacey J Winham; Boris Winterhoff; Alicia Beeghly-Fadiel; Javier Benitez; Andrew Berchuck; James D Brenton; Robert Brown; Jenny Chang-Claude; Georgia Chenevix-Trench; Anna deFazio; Peter A Fasching; María J García; Simon A Gayther; Marc T Goodman; Jacek Gronwald; Michelle J Henderson; Beth Y Karlan; Linda E Kelemen; Usha Menon; Sandra Orsulic; Paul D P Pharoah; Nicolas Wentzensen; Anna H Wu; Joellen M Schildkraut; Mary Anne Rossing; Gottfried E Konecny; David G Huntsman; Ruby Yun-Ju Huang
Journal:  Clin Cancer Res       Date:  2020-06-17       Impact factor: 13.801

Review 3.  Macrophage Polarization in the Development and Progression of Ovarian Cancers: An Overview.

Authors:  Huiyan Cheng; Zhichao Wang; Li Fu; Tianmin Xu
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

4.  A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.

Authors:  Yinglian Pan; Li Ping Jia; Yuzhu Liu; Yiyu Han; Qian Li; Qin Zou; Zhongpei Zhang; Jin Huang; Qingchun Deng
Journal:  J Ovarian Res       Date:  2020-09-19       Impact factor: 4.234

Review 5.  Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).

Authors:  Hongyi Li; Yu Liu; Yang Wang; Xia Zhao; Xiaorong Qi
Journal:  Oncol Rep       Date:  2021-08-26       Impact factor: 3.906

Review 6.  SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.

Authors:  Boshu Sun; Liangliang Xu; Wenhui Bi; Wen-Bin Ou
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

7.  CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer.

Authors:  Bipradeb Singha; Sandra L Harper; Aaron R Goldman; Benjamin G Bitler; Katherine M Aird; Mark E Borowsky; Mark G Cadungog; Qin Liu; Rugang Zhang; Stephanie Jean; Ronny Drapkin; David W Speicher
Journal:  Sci Rep       Date:  2018-10-03       Impact factor: 4.379

8.  Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.

Authors:  Sarah L Hulin-Curtis; James A Davies; Davor Nestić; Emily A Bates; Alexander T Baker; Tabitha G Cunliffe; Dragomira Majhen; John D Chester; Alan L Parker
Journal:  Cancer Gene Ther       Date:  2020-01-06       Impact factor: 5.987

Review 9.  The Evolution of Ovarian Carcinoma Subclassification.

Authors:  Martin Köbel; Eun Young Kang
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

Review 10.  A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).

Authors:  Luca Falzone; Giuseppa Scandurra; Valentina Lombardo; Giuseppe Gattuso; Alessandro Lavoro; Andrea Benedetto Distefano; Giuseppe Scibilia; Paolo Scollo
Journal:  Int J Oncol       Date:  2021-06-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.